Interim studies on medical use of cannabis have been requested by four Oklahoma legislators.
In the Oklahoma House of Representatives, Rep. Jon Echols (R-Oklahoma City) proposed an interim study in the Public Health Committee on allowing medical trials in the state of Oklahoma for the use of non-intoxicating CBD oil for severe seizure disorders in children. Rep. Joe Dorman (D-Rush Springs) proposed a study on medical treatments for children with seizures and regulation of experimental medicines. Rep. Todd Thomsen (R-Ada) proposed a study on medical marijuana for children. Their study requests have been combined.
In addition, Sen. Patrick Anderson (R-Enid) has proposed a study on the use of cannabinoid extract for the treatment of epilepsy and diabetes.
During a February Senate Appropriations Subcommittee on Select Agencies hearing on medical cannabis, scheduled by Anderson, testimony was heard from families of children with Dravet syndrome, a catastrophic form of epilepsy, and experts in the field of cannabidiol research. The experts included Josh Stanley, a developer of strains of hemp plants high in cannabidiol who said disorders that respond to cannabidiol treatment include seizure disorders and diabetes; and Mark Rosenfeld, founder and CEO of ISA Scientific, who said his research has shown cannabidiol has therapeutic potential in treatment of heart attacks, pain, diabetes, atherosclerosis, inflammatory bowel disease, cancer and epilepsy.
Anderson said the interim study has not yet been scheduled, but he anticipates it will take place some time in the fall.
Anderson said he is working to designate who will be invited to speak with committee members, but the list may include Perry resident Marty Piel, who testified at the February hearing how cannabidiol — an oil tincture made from cannabis extract — placed under the girl’s tongue, has greatly eased her seizures from Dravet syndrome.
Others Anderson is considering include experts from the Oklahoma Medical Research Foundation, the Harold Hamm Diabetes Center and cannabis researchers including Brent Reynolds and Dennis Steindler, both recently hired by Denver-based United Cannabis Corporation to help design studies leading to potential FDA approval to market medicinal marijuana drugs in legal communities.